Ifp Advisors, Inc Savara Inc Transaction History

Ifp Advisors, Inc

0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 04, 2025	BUY	$2.94 - $4.07 $0 - $0	0 New	0 $0
Q2 2023 Aug 04, 2023	BUY	$1.69 - $3.24 $1,014 - $1,944	600 New	600 $1,000
Q3 2021 Oct 06, 2021	SELL	$1.18 - $1.64 $0 - $0	0 Closed	0 $0
Q2 2021 Jul 13, 2021	BUY	$1.51 - $2.29 $0 - $0	0 New	0 $0
Q1 2021 Apr 30, 2021	BUY	$1.17 - $2.33 $0 - $0	0 New	0 $0
Q4 2020 Jan 25, 2021	BUY	$1.0 - $1.47 $0 - $0	0 New	0 $0
Q3 2020 Oct 29, 2020	BUY	$1.09 - $2.21 $0 - $0	0 New	0 $0
Q2 2020 Aug 05, 2020	SELL	$1.8 - $3.05 $75 - $128	-42 Closed	0 $0
Q3 2019 Nov 07, 2019	SELL	$2.16 - $3.2 $216 - $320	-100 Reduced 70.42%	42 $0
Q1 2019 May 15, 2019	SELL	$6.71 - $8.6 $281 - $361	-42 Reduced 22.83%	142 $1,000
Q2 2018 Aug 07, 2018	SELL	$8.55 - $13.76 $188 - $302	-22 Reduced 10.68%	184 $0
Q1 2018 Jun 03, 2019	BUY	$8.99 - $14.95 $197 - $328	22 Added 11.96%	206 $3,000
Q1 2018 May 09, 2018	SELL	$8.99 - $14.95 $197 - $328	-22 Reduced 10.68%	184 $0
Q4 2017 Jan 24, 2018	SELL	$8.26 - $16.76 $49 - $100	-6 Reduced 2.83%	206 $0
Q3 2017 Oct 30, 2017	SELL	$5.1 - $9.55 $775 - $1,451	-152 Reduced 41.76%	212 $2,000
Q2 2017 Jun 03, 2019	BUY	N/A	222 Added 156.34%	364 $2,000
Q1 2016 Jun 03, 2019	BUY	N/A	142	142 $1,000

129

151M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $328M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.